← Back to Search

Genetic Testing

Non-euploid Embryo Transfer for Aneuploidy and Mosaicism (TAME Trial)

N/A

Recruiting

Led By Ruth Lathi, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No acceptable euploid embryos available

Available aneuploid or mosaic embryos

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 years

Awards & highlights

TAME Trial Summary

This trial looks at how often embryos that are reported as abnormal by preimplantation genetic testing actually result in a live birth, and whether those babies have any health or developmental issues.

Who is the study for?

This trial is for individuals who can travel to Stanford, speak English fluently, and have aneuploid or mosaic embryos ready for transfer but no healthy euploid embryos available. It's not open to those using a gestational carrier, living outside the U.S., or with embryos diagnosed with Trisomy 18, Trisomy 13, or Triploidy.Check my eligibility

What is being tested?

The study is testing the outcomes of transferring non-euploid (abnormal) embryos into participants compared to normal (euploid) embryo transfers. The focus is on live birth rates and any health or developmental issues in children up to five years post-birth.See study design

What are the potential side effects?

Since this trial involves pregnancy through embryo transfer, potential side effects are related to fertility procedures and pregnancy complications rather than medication side effects.

TAME Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have any healthy embryos for use.

Select...

I have embryos that are not typical in their chromosome number.

TAME Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pregnancy Rate

Secondary outcome measures

Live birth rate

Obstetric complications

Pediatric Development

TAME Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Non-euploid TransferExperimental Treatment1 Intervention

Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).

Group II: Euploid TransferActive Control1 Intervention

Patients desiring pregnancy who are undergoing euploid embryo transfer

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,400 Previous Clinical Trials

17,341,529 Total Patients Enrolled

Ruth Lathi, MDPrincipal InvestigatorStanford University

1 Previous Clinical Trials

100 Total Patients Enrolled

Media Library

Euploid Transfer (Genetic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT04109846 — N/A

Aneuploidy Research Study Groups: Non-euploid Transfer, Euploid Transfer

Aneuploidy Clinical Trial 2023: Euploid Transfer Highlights & Side Effects. Trial Name: NCT04109846 — N/A

Euploid Transfer (Genetic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04109846 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research initiative seek out individuals above the age of 50?

"This medical trial will include patients that are 18 and older, but below the age of 55."

Answered by AI

Are individuals currently being accepted to participate in this experiment?

"This medical experiment, which was initially published on April 11th 2019, is still open and actively looking for participants. The trial's information has been modified most recently on January 27th 2022 according to clinicaltrials.gov."

Answered by AI

To whom is this clinical trial open for participation?

"This trial aims to enroll 300 individuals aged 18-55 with aneuploidy. In addition, these participants must have available aneuploid or mosaic embryos, not possess any acceptable euploid specimens, be willing to travel for treatment at Stanford University, and understand English."

Answered by AI

To what extent is the current research being conducted involving human participants?

"Affirmative. Information hosted on clinicaltrials.gov displays that the study, which was first advertised on April 11th 2019 is currently recruiting participants; 300 volunteers are needed at a single medical centre for enrollment."

Answered by AI

Recent research and studies

European Journal of Medical GeneticsJournal

Clinical Outcomes After the Transfer of Blastocysts Characterized as Mosaic by High Resolution Next Generation Sequencing- Further Insights

Munné, Santiago, Francesca Spinella, Jamie Grifo, John Zhang, Monica Parriego Beltran, Elpida Fragouli, and Francesco Fiorentino. 2020. “Clinical Outcomes After the Transfer of Blastocysts Characterized as Mosaic by High Resolution Next Generation Sequencing- Further Insights”. European Journal of Medical Genetics. Elsevier BV. doi:10.1016/j.ejmg.2019.103741.

New England Journal of MedicineJournal

Healthy Babies After Intrauterine Transfer of Mosaic Aneuploid Blastocysts

Greco, Ermanno, Maria Giulia Minasi, and Francesco Fiorentino. 2015. “Healthy Babies After Intrauterine Transfer of Mosaic Aneuploid Blastocysts”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc1500421.

Journal of Assisted Reproduction and GeneticsJournal

Rates of Live Birth After Mosaic Embryo Transfer Compared with Euploid Embryo Transfer

Zhang, Lei, Daimin Wei, Yueting Zhu, Yuan Gao, Junhao Yan, and Zi-Jiang Chen. 2018. “Rates of Live Birth After Mosaic Embryo Transfer Compared with Euploid Embryo Transfer”. Journal of Assisted Reproduction and Genetics. Springer Science and Business Media LLC. doi:10.1007/s10815-018-1322-2.

Fertility and SterilityJournal